SRMS142-based solid lipid microparticles: Application in oral delivery of glibenclamide to diabetic rats

Nnamani P.O., Attama A.A., Ibezim E.C., Adikwu M.U. European Journal of Pharmaceutics and Biopharmaceutics, In Press, Corrected Proof, Available online 8 June 2010

SRMS142-based solid lipid microparticles: Application in oral delivery of glibenclamide to diabetic rats Nnamani P.O., Attama A.A., Ibezim E.C., Adikwu M.U. European Journal of Pharmaceutics and Biopharmaceutics, In Press, Corrected Proof, Available online 8 June 2010 P90Gylation refers to the modification of lipid molecules by one or more phospholipid chains. Phospholipon® 90G (P90G) contains about 94.0% of phosphatidylcholine stabilized with 0.1% ascorbyl palmitate and is a safe (GRAS) FDA-approved parenteral excipient with wide applications in drug delivery. P90Gylated-Softisan® 142 conjugate, otherwise referred to as (SRMS142), has numerous advantages: wetting, solubilization, drug stabilization, emulsification, and modified release. Here, we report an evaluation of solid lipid microparticles (SLMs) formulated from SRMS142 systems as an alternative carrier system for oral glibenclamide administration in diabetic rats. The result of our findings showed that SRMS142 generated an imperfect matrix with numerous spaces that accommodated glibenclamide in a concentration-dependent manner up to 60.58%. The blood glucose–lowering effect of the SLMs was higher than that of a commercial sample.